204 related articles for article (PubMed ID: 11514139)
1. 1,4-Disubstituted imidazoles are potential antibacterial agents functioning as inhibitors of enoyl acyl carrier protein reductase (FabI).
Heerding DA; Chan G; DeWolf WE; Fosberry AP; Janson CA; Jaworski DD; McManus E; Miller WH; Moore TD; Payne DJ; Qiu X; Rittenhouse SF; Slater-Radosti C; Smith W; Takata DT; Vaidya KS; Yuan CC; Huffman WF
Bioorg Med Chem Lett; 2001 Aug; 11(16):2061-5. PubMed ID: 11514139
[TBL] [Abstract][Full Text] [Related]
2. Inhibitors of bacterial enoyl acyl carrier protein reductase (FabI): 2,9-disubstituted 1,2,3,4-tetrahydropyrido[3,4-b]indoles as potential antibacterial agents.
Seefeld MA; Miller WH; Newlander KA; Burgess WJ; Payne DJ; Rittenhouse SF; Moore TD; DeWolf WE; Keller PM; Qiu X; Janson CA; Vaidya K; Fosberry AP; Smyth MG; Jaworski DD; Slater-Radosti C; Huffman WF
Bioorg Med Chem Lett; 2001 Sep; 11(17):2241-4. PubMed ID: 11527706
[TBL] [Abstract][Full Text] [Related]
3. The enoyl-[acyl-carrier-protein] reductase (FabI) of Escherichia coli, which catalyzes a key regulatory step in fatty acid biosynthesis, accepts NADH and NADPH as cofactors and is inhibited by palmitoyl-CoA.
Bergler H; Fuchsbichler S; Högenauer G; Turnowsky F
Eur J Biochem; 1996 Dec; 242(3):689-94. PubMed ID: 9022698
[TBL] [Abstract][Full Text] [Related]
4. Discovery of aminopyridine-based inhibitors of bacterial enoyl-ACP reductase (FabI).
Miller WH; Seefeld MA; Newlander KA; Uzinskas IN; Burgess WJ; Heerding DA; Yuan CC; Head MS; Payne DJ; Rittenhouse SF; Moore TD; Pearson SC; Berry V; DeWolf WE; Keller PM; Polizzi BJ; Qiu X; Janson CA; Huffman WF
J Med Chem; 2002 Jul; 45(15):3246-56. PubMed ID: 12109908
[TBL] [Abstract][Full Text] [Related]
5. Phenylimidazole derivatives of 4-pyridone as dual inhibitors of bacterial enoyl-acyl carrier protein reductases FabI and FabK.
Kitagawa H; Ozawa T; Takahata S; Iida M; Saito J; Yamada M
J Med Chem; 2007 Sep; 50(19):4710-20. PubMed ID: 17713898
[TBL] [Abstract][Full Text] [Related]
6. Discovery of 4-Pyridone derivatives as specific inhibitors of enoyl-acyl carrier protein reductase (FabI) with antibacterial activity against Staphylococcus aureus.
Takahata S; Iida M; Yoshida T; Kumura K; Kitagawa H; Hoshiko S
J Antibiot (Tokyo); 2007 Feb; 60(2):123-8. PubMed ID: 17420562
[TBL] [Abstract][Full Text] [Related]
7. Indole naphthyridinones as inhibitors of bacterial enoyl-ACP reductases FabI and FabK.
Seefeld MA; Miller WH; Newlander KA; Burgess WJ; DeWolf WE; Elkins PA; Head MS; Jakas DR; Janson CA; Keller PM; Manley PJ; Moore TD; Payne DJ; Pearson S; Polizzi BJ; Qiu X; Rittenhouse SF; Uzinskas IN; Wallis NG; Huffman WF
J Med Chem; 2003 Apr; 46(9):1627-35. PubMed ID: 12699381
[TBL] [Abstract][Full Text] [Related]
8. Phenylimidazole derivatives as specific inhibitors of bacterial enoyl-acyl carrier protein reductase FabK.
Ozawa T; Kitagawa H; Yamamoto Y; Takahata S; Iida M; Osaki Y; Yamada K
Bioorg Med Chem; 2007 Dec; 15(23):7325-36. PubMed ID: 17892940
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of the Staphylococcus aureus NADPH-dependent enoyl-acyl carrier protein reductase by triclosan and hexachlorophene.
Heath RJ; Li J; Roland GE; Rock CO
J Biol Chem; 2000 Feb; 275(7):4654-9. PubMed ID: 10671494
[TBL] [Abstract][Full Text] [Related]
10. Discovery of a potent enoyl-acyl carrier protein reductase (FabI) inhibitor suitable for antistaphylococcal agent.
Kim YG; Seo JH; Kwak JH; Shin KJ
Bioorg Med Chem Lett; 2015 Oct; 25(20):4481-6. PubMed ID: 26343826
[TBL] [Abstract][Full Text] [Related]
11. Discovery of a novel and potent class of FabI-directed antibacterial agents.
Payne DJ; Miller WH; Berry V; Brosky J; Burgess WJ; Chen E; DeWolf WE; Fosberry AP; Greenwood R; Head MS; Heerding DA; Janson CA; Jaworski DD; Keller PM; Manley PJ; Moore TD; Newlander KA; Pearson S; Polizzi BJ; Qiu X; Rittenhouse SF; Slater-Radosti C; Salyers KL; Seefeld MA; Smyth MG; Takata DT; Uzinskas IN; Vaidya K; Wallis NG; Winram SB; Yuan CC; Huffman WF
Antimicrob Agents Chemother; 2002 Oct; 46(10):3118-24. PubMed ID: 12234833
[TBL] [Abstract][Full Text] [Related]
12. Structural and biological evaluation of a novel series of benzimidazole inhibitors of Francisella tularensis enoyl-ACP reductase (FabI).
Mehboob S; Song J; Hevener KE; Su PC; Boci T; Brubaker L; Truong L; Mistry T; Deng J; Cook JL; Santarsiero BD; Ghosh AK; Johnson ME
Bioorg Med Chem Lett; 2015 Mar; 25(6):1292-6. PubMed ID: 25677657
[TBL] [Abstract][Full Text] [Related]
13. Rational design of broad spectrum antibacterial activity based on a clinically relevant enoyl-acyl carrier protein (ACP) reductase inhibitor.
Schiebel J; Chang A; Shah S; Lu Y; Liu L; Pan P; Hirschbeck MW; Tareilus M; Eltschkner S; Yu W; Cummings JE; Knudson SE; Bommineni GR; Walker SG; Slayden RA; Sotriffer CA; Tonge PJ; Kisker C
J Biol Chem; 2014 Jun; 289(23):15987-6005. PubMed ID: 24739388
[TBL] [Abstract][Full Text] [Related]
14. Ligand- and Structure-Based Approaches of Escherichia coli FabI Inhibition by Triclosan Derivatives: From Chemical Similarity to Protein Dynamics Influence.
Kronenberger T; de Oliveira Fernades P; Drumond Franco I; Poso A; Gonçalves Maltarollo V
ChemMedChem; 2019 Dec; 14(23):1995-2004. PubMed ID: 31670463
[TBL] [Abstract][Full Text] [Related]
15. FabI (enoyl acyl carrier protein reductase) - A potential broad spectrum therapeutic target and its inhibitors.
Rana P; Ghouse SM; Akunuri R; Madhavi YV; Chopra S; Nanduri S
Eur J Med Chem; 2020 Dec; 208():112757. PubMed ID: 32883635
[TBL] [Abstract][Full Text] [Related]
16. The food-grade antimicrobial xanthorrhizol targets the enoyl-ACP reductase (FabI) in Escherichia coli.
Yogiara ; Mordukhova EA; Kim D; Kim WG; Hwang JK; Pan JG
Bioorg Med Chem Lett; 2020 Dec; 30(24):127651. PubMed ID: 33130290
[TBL] [Abstract][Full Text] [Related]
17. Meleagrin, a new FabI inhibitor from Penicillium chryosogenum with at least one additional mode of action.
Zheng CJ; Sohn MJ; Lee S; Kim WG
PLoS One; 2013; 8(11):e78922. PubMed ID: 24312171
[TBL] [Abstract][Full Text] [Related]
18. Studies of Staphylococcus aureus FabI inhibitors: fragment-based approach based on holographic structure-activity relationship analyses.
Kronenberger T; Asse LR; Wrenger C; Trossini GH; Honorio KM; Maltarollo VG
Future Med Chem; 2017 Feb; 9(2):135-151. PubMed ID: 28128024
[TBL] [Abstract][Full Text] [Related]
19. A novel series of enoyl reductase inhibitors targeting the ESKAPE pathogens, Staphylococcus aureus and Acinetobacter baumannii.
Kwon J; Mistry T; Ren J; Johnson ME; Mehboob S
Bioorg Med Chem; 2018 Jan; 26(1):65-76. PubMed ID: 29162308
[TBL] [Abstract][Full Text] [Related]
20. Virtual screening of antibacterial compounds by similarity search of Enoyl-ACP reductase (FabI) inhibitors.
Asse Junior LR; Kronenberger T; Magalhães Serafim MS; Sousa YV; Franco ID; Valli M; Silva Bolzani VD; Monteiro GC; Bruno Prates JL; Kroon EG; Fernandes Mota BE; Santos Ferreira DD; de Oliveira RB; Maltarollo VG
Future Med Chem; 2020 Jan; 12(1):51-68. PubMed ID: 31729258
[No Abstract] [Full Text] [Related]
[Next] [New Search]
